Clinical Glomerulonephritis 2

THE CHRONICITY INDEX FOR LN BIOPSIES SHOULD BE MODIFIED TO EXCLUDE FIBROUS CRESCENTS?

NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL

EFFICACY AND SAFETY OF RAVULIZUMAB IN A PHASE 2 RANDOMIZED CONTROLLED TRIAL IN IgA NEPHROPATHY

NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL

NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2-YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL

ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY

Combined Activity, Recovery, and Chronicity Kidney Biopsy Grading for Prognostic Assessment in ANCA-associated Vasculitis with Glomerulonephritis (AAV-GN)

NEUROPSYCHIATRIC SLE (NPSLE) IN CHILDREN AND ADOLESCENTS WITH LUPUS NEPHRITIS

EXOSTOSIN 1- AND 2- POSITIVE MEMBRANOUS NEPHROPATHY IN CHINESE PATIENTS

SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL

A novel approach to induce early remission in high-risk primary membranous nephropathy

ANGIOTENSIN II PROMOTES PODOCYTE APOPTOSIS THROUGH THE MODULATION OF CD2AP AND AMPK

SPARSENTAN RECEPTOR OCCUPANCY MODELING, CLINICAL ACTIONS, AND SAFETY

EVALUATION OF CD68 AS A MARKER OF ACTIVITY IN LUPUS GLOMERULONEPHRITIS, (IMMUNOHISTOCHEMICAL STUDY)

THE GENETIC LANDSCAPE OF ALPORT SYNDROME IN INDIAN PATIENTS WITH PHENOTYPIC CORRELATION

PRELIMINARY FINDINGS FROM THE PHASE 2 EPPIK STUDY OF SPARSENTAN IN PEDIATRIC PATIENTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES

CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)

eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL

ASSIST: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CROSSOVER TRIAL OF ATRASENTAN IN PATIENTS WITH IGA NEPHROPATHY (IGAN) ON SGLT2I

ELEVATED MBL LEVELS AND ITS ASSOCIATION WITH ENDOTHELIAL DYSFUNCTION IN PMN

EFFICACY OF 12-WEEK PEGCETACOPLAN IN KIDNEY TRANSPLANT RECIPIENTS WITH RECURRENT C3 GLOMERULOPATHY (C3G) OR IMMUNE COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN)

TREATMENT PATTERNS IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY - EVIDENCE FROM REAL-WORLD DATA

REAL-WORLD ANALYSIS OF PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY

TREATMENT GOALS FROM THE PERSPECTIVE OF IMMUNOGLOBULIN A NEPHROPATHY PATIENTS - RESULTS FROM A REAL-WORLD STUDY

POVETACICEPT, AN ENHANCED DUAL BAFF/APRIL ANTAGONIST, IN AUTOANTIBODY-ASSOCIATED GLOMERULONEPHRITIS

EFFECT OF CORTICOSTEROIDS ON KIDNEY AND SAFETY OUTCOMES IN IGA NEPHROPATHY ACROSS DIFFERENT LEVELS OF PROTEINURIA AND EGFR: A POST HOC ANALYSIS OF THE TESTING STUDY

MACHINE-LEARNING ASSISTED DISCOVERY UNVEILS NOVEL INTERPLAY BETWEEN GUT MICROBIOTA AND BRANCHED-CHAIN AMINO ACIDS METABOLISM IN DIABETIC KIDNEY DISEASE